초록 ▼

A method for imaging the blood flow in a patient receiving radiomedical treatment, including forming a first and a second plurality of generally spherical biologically stable members, with each respective member of the first plurality includes a first non-radioactive isotope distributed substantiall

A method for imaging the blood flow in a patient receiving radiomedical treatment, including forming a first and a second plurality of generally spherical biologically stable members, with each respective member of the first plurality includes a first non-radioactive isotope distributed substantially uniformly therein that, upon being subjected to an effective amount of neutron irradiation, emits a therapeutic intensity and amount of beta or gamma radiation and wherein each respective member of the second plurality includes a second non-radioactive isotope distributed substantially uniformly therethrough that, upon being subjected to an effective amount of neutron irradiation, emits a detectable intensity and amount of positron radiation. The first and second members are subjected to an effective amount of neutron radiation and the irradiated first and second pluralities of irradiated first and second members are introduced into a patient's circulatory system upstream of a desired treatment site. The second plurality of irradiated members is imaged via positron emission tomography. The second isotope, once activated by neutron irradiation, has a maximum half-life of about four days.

대표청구항 ▼

1. A substantially spherical body for imaging blood flow in a living organism, comprising: a biologically stable glass matrix formed from materials that do not become significantly radioactive during neutron irradiation; andat least one non-radioactive isotope distributed substantially uniformly thr

1. A substantially spherical body for imaging blood flow in a living organism, comprising: a biologically stable glass matrix formed from materials that do not become significantly radioactive during neutron irradiation; andat least one non-radioactive isotope distributed substantially uniformly throughout the matrix and characterized by emission of a detectable amount of positron radiation and a maximum half-life of about four days upon neutron irradiation;wherein the at least one non-radioactive isotope includes 63Cu and wherein the glass is a substantially boron-free aluminosilicate. 2. The substantially spherical body of claim 1 wherein the non-radioactive isotope is further characterized by a substantial lack of nuclear gamma emission upon neutron irradiation. 3. The substantially spherical body of claim 1 wherein the non-radioactive isotope is further characterized by an emission of positron radiation with a mean energy of below about 400 keV upon neutron irradiation. 4. The substantially spherical body of claim 1 wherein the non-radioactive isotope is further characterized by an emission of positron radiation with a mean energy of between about 250 keV and about 300 keV upon neutron irradiation. 5. The substantially spherical body of claim 1 wherein the biologically stable matrix has a maximum dimension of between about 5 micrometers and about 75 micrometers. 6. An injectable positron source for imaging blood flow in a living organism, comprising: a plurality of substantially spherical biologically stable glass portions; anda predetermined amount of positron emitters distributed in each respective portion;wherein the plurality of substantially spherical biologically stable portions emit sufficient positron radiation for PET imaging of an organ andwherein each respective substantially spherical biologically stable portion has a maximum dimension of between about 5 micrometers and about 75 micrometers; andwherein the positron emitters are 64Cu atoms and wherein the glass is a substantially boron-free aluminosilicate. 7. The positron source of claim 6 wherein the glass includes between about 0.1 weight percent and 30 weight percent copper oxide. 8. The positron source of claim 6 wherein the positron emitters are introduced into the respective biologically stable portions as nonradioactive isotopes and wherein the nonradioactive isotopes are activated to become positron emitters through neutron irradiation. 9. The positron source of claim 6 wherein the respective biologically stable portions also include therapeutic nonradioactive isotopes; wherein the therapeutic nonradioactive isotopes are activated to become therapeutic radiation emitters through neutron irradiation; and wherein the therapeutic radiation is selected from the group including beta particles, gamma rays, and combinations thereof. 10. A substantially spherical body for administering therapeutic radiation and imaging blood flow in a living organism, comprising: a biologically stable vitreous matrix formed from materials that do not become significantly radioactive during neutron irradiation;a first non-radioactive Cu-63 isotope distributed substantially uniformly throughout the matrix and characterized by emission of a detectable amount of positron radiation and a maximum half-life of about four days upon neutron irradiation; anda second non-radioactive isotope distributed substantially uniformly throughout the matrix and characterized by emission of an effective amount of therapeutic radiation and a maximum half-life of about four days upon neutron irradiation;wherein the therapeutic radiation is selected from the group including gamma radiation, beta radiation, and a combination of the beta and gamma radiation and wherein the biologically stable vitreous matrix is a substantially boron-free aluminosilicate glass. 11. The substantially spherical body of claim 10, wherein the second non-radioactive isotope is Y-89. 12. The substantially spherical body of claim 10, wherein the first non-radioactive isotope is distributed substantially uniformly throughout the matrix as a component of natural copper. 13. The substantially spherical body of claim 10, wherein the first non-radioactive isotope is distributed substantially uniformly throughout the matrix as an oxide.